Bluebird Bio Directors 'Grossly' Overpaid, Chancery Suit Says
A Bluebird Bio Inc. investor filed a derivative suit in Delaware Chancery Court on Monday claiming the gene therapy research and development company's directors are "grossly" overcompensated in comparison to similarly...To view the full article, register now.
Already a subscriber? Click here to view full article